Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers.
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers. The IBA configuration, dubbed Proteus Nano, starkly contrasts the often two-story proton therapy centers that occupy as much as 100,000 square feet. The company is framing Proteus Nano as requiring a much smaller footprint and imposing a lower acquisition cost, while still providing the highly accelerated proton beams needed to kill cancer tumors.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.